Key findings

• MOH added 13 severe genetic conditions to the approved PGT list as of October 31, 2025, raising the total to 169 conditions.
• The new conditions include six single gene defects linked to higher risks of breast cancer and mild brittle bone disease, alongside seven chromosomal abnormalities increasing miscarriage risk.
• Eligible couples can receive up to 75% co-funding for approved PGT costs at public assisted reproduction centres.
• Testing cannot be done for social reasons, such as gender selection or genetic enhancement.

The Ministry of Health, MOH expands genetic conditions for PGT only for severe genetic conditions that are highly likely to manifest in affected individuals and for which treatment options remain limited. Among the newly included conditions, mutations in the RAD51D gene present a notable example carriers may face significantly elevated lifetime risks of breast and ovarian cancers, with studies showing mutations in RAD51D in 0.3% of breast cancer patients and 1% of ovarian cancer patients. Other expanded approvals include type 1 osteogenesis imperfecta, a mild form of brittle bone disease causing bone fragility and frequent fractures, resulting from mutations in the COL1A1 gene.

Seven newly approved categories involving chromosomal structural abnormalities added by Singapore's Ministry of Health (MOH) for preimplantation genetic testing (PGT) specifically encompass structural changes in chromosomes that elevate the risk of recurrent miscarriage or cause developmental problems in offspring. These abnormalities typically include the following:

Breakdown of the 13 New Conditions:

• Six are single-gene defects that can put a person at greater risk of conditions like breast cancer and mild brittle bone disease
• Seven are chromosomal abnormalities that carry an increased risk of miscarriage, which would likely make the embryos unsuitable for IVF
  

Financial support is available for couples where at least one spouse is a Singapore citizen meeting clinical criteria. Since July 2022, they can access up to 75% government co-funding for PGT at public assisted reproduction centres KK Women’s and Children’s Hospital, National University Hospital, and Singapore General Hospital. Additionally, MediSave funds can be used within withdrawal limits regardless of public or private treatment settings.

Embryos identified with gene mutations or chromosomal abnormalities may still sometimes be eligible for implantation depending on the condition and genetic inheritance pattern. For example, embryos with one abnormal gene copy in osteogenesis imperfecta are unsuitable for transfer, while those with one affected gene in some recessive conditions might be considered after counseling. Embryos carrying two abnormal copies for recessive diseases or severe defects will not be implanted, and affected embryos are not preserved.

This development by MOH expands genetic conditions and IVF, aiming to reduce transmission of serious inheritable diseases while maintaining ethical constraints. It reflects ongoing advances in genetic testing technology integrated into fertility care, providing couples greater assurance and choice before embryo implantation.